Antiangiogenesis Combined with Immunotherapy to Treat Advanced Small-Cell Carcinoma of the Esophagus Resistant to Chemotherapy: According to the Guidance of Next-Generation Sequencing

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Medgyesy CD, Wolff RA, Putnam JB, Alani JA. Small cell carcinoma of the esophagus: the University of Texas M.D. Anderson Cancer Center experience and literature review. Cancer. 2000;88:262–267. doi:10.1002/(SICI)1097-0142(20000115)88:2<262::AID-CNCR3>3.0.CO;2-K
   PubMed Web of Science ®Google Scholar
• Bennouna J, Bardet E, Deguiral P, Douillard JY. Small cell carcinoma of the esophagus: analysis of 10 cases and review of the published data. Am J Clin Oncol. 2000;23:455–459. doi:10.1097/00000421-200010000-00005
   PubMed Web of Science ®Google Scholar
• Chow V, Law S, Lam KY, Luk JM, Wong J. Telomerase activity in small cell esophageal carcinoma. Dis Esophagus. 2001;14:139–142. doi:10.1046/j.1442-2050.2001.00172.x
   PubMed Web of Science ®Google Scholar
• Mitani M, Kuwabara Y, Shinoda N, Sato A, Fujii Y. Longterm survivors after the resection of limited esophageal small cell carcinoma. Dis Esophagus. 2000;13:259–261. doi:10.1046/j.1442-2050.2000.00124.x
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qiu B, Liu H, Xiao W, Hu Y, Liu M. Primary small cell carcinoma of the esophagus: review of 64 cases from a single institution. Dis Esophagus. 2014;27:152–158. doi:10.1111/dote.12069
   PubMed Web of Science ®Google Scholar
• Pantvaidya GH, Pramesh CS, Deshpande MS, Jambhekar NA, Sharma S, Deshpande RK. Small cell carcinoma of the esophagus: the Tata Memorial Hospital experience. Ann Thorac Surg. 2002;74:1924–1927. doi:10.1016/S0003-4975(02)04061-4
   PubMed Web of Science ®Google Scholar
• Xiao Q, Xiao H, Ouyang S, Tang J, Zhang B, Wang H. Primary small cell carcinoma of the esophagus: comparison between a Chinese cohort and surveillance, epidemiology, and end results (SEER) data. Cancer Med. 2019;8(3):1074–1085. doi:10.1002/cam4.2001
   PubMed Web of Science ®Google Scholar
• Wong AT, Shao M, Rineer J, Osborn V, Schwartz D, Schreiber D. Treatment and survival outcomes of small cell carcinoma of the esophagus: an analysis of the National Cancer Data Base. Dis Esophagus. 2017;30(2):1–5. doi:10.1111/dote.12487
   Web of Science ®Google Scholar
• Chen BQ, Yang H, Ma HL, et al. Radiotherapy for small cell carcinoma of the esophagus: outcomes and prognostic factors from a retrospective study. Radiat Oncol. 2019;14:210–217. doi:10.1186/s13014-019-1415-9
   PubMed Web of Science ®Google Scholar
• Yu C, Liu X, Yang J, et al. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. Front Immunol. 2019;7(10):990. doi:10.3389/fimmu.2019.00990
   Google Scholar
• Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, Phase 2 trial. Lancet Oncol. 2019;20(5):711–718. doi:10.1016/S1470-2045(19)30020-8
   PubMed Web of Science ®Google Scholar
• Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer. 2019;106:144–159. doi:10.1016/j.ejca.2018.11.002
   PubMed Web of Science ®Google Scholar
• Shen G, Zheng F, Ren DF, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120–127. doi:10.1186/s13045-018-0664-7
   PubMed Web of Science ®Google Scholar
• Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRb and FGFR1. Gene. 2018;654:77–86. doi:10.1016/j.gene.2018.02.026
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK, Goodrich DW. Cell cycle and beyond: exploiting new RB1 controlled mechanisms for cancer therapy. Trends Cancer. 2019;5(5):308–324. doi:10.1016/j.trecan.2019.03.005
   PubMed Web of Science ®Google Scholar
• Derks JL, Leblay N, Thunnissen E, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2017;24(1):33–42. doi:10.1158/1078-0432.CCR-17-1921
   PubMed Web of Science ®Google Scholar
• Attar N, Kurdistani SK. Exploitation of EP300 and CREBBP lysine acetyltransferases by cancer. CSH Perspect Med. 2017;7:a026534.
   Google Scholar
• Wen J, Min XJ, Shen M, et al. ACLY facilitates colon cancer cell metastasis by CTNNB1. J Exp Clin Cancer Res. 2019;38:401. doi:10.1186/s13046-019-1391-9
   PubMed Web of Science ®Google Scholar
• Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23(12):3012–3024. doi:10.1158/1078-0432.CCR-16-2554
   PubMed Web of Science ®Google Scholar
• Dabir S, Kresak A, Yang M, Fu PF, Wildey G, Dowlati A. CD30 is a potential therapeutic target in malignant mesothelioma. Mol Cancer Ther. 2015;14(3):740–746. doi:10.1158/1535-7163.MCT-14-0972
   PubMed Web of Science ®Google Scholar
• Ma GX, Liu HT, Hua QH, et al. KCNMA1 cooperating with PTK2 is a novel tumor suppressor in gastric cancer and is associated with disease outcome. Mol Cancer. 2017;16:46–56. doi:10.1186/s12943-017-0613-z
   PubMed Web of Science ®Google Scholar
• Haikala HM, Anttila JM, Marques E, et al. Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. Nat Commun. 2019;10:620–637. doi:10.1038/s41467-019-08541-2
   PubMed Web of Science ®Google Scholar
• Ocak S, Yamashita H, Udyavar AR, et al. DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene. 2010;29:6331–6342. doi:10.1038/onc.2010.362
   PubMed Web of Science ®Google Scholar
• Park JH, Lee BL, Yoon J, et al. Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol. 2010;41:1664–1673. doi:10.1016/j.humpath.2010.06.004
   PubMed Web of Science ®Google Scholar